title: Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts.
abstract: Thrombolytic therapy has been documented to reduce acute myocardial infarct size. The previously established relation between initial ST segment elevation and final electrocardiographic (ECG) myocardial infarct size in patients without coronary reperfusion might therefore be altered by thrombolytic therapy. The effect of intravenous streptokinase on this relation was therefore studied in 73 patients with initial acute myocardial infarction who had participated in the Second International Study of Infarct Survival (ISIS-2). Patients who received streptokinase were considered as one group and patients who did not receive streptokinase as a control group. Final myocardial infarct size, which was estimated from the QRS score, was predicted from the admission standard ECG by previously developed formulas based on ST segment elevation. In the 40 control patients there was no change from ST-predicted to final QRS-estimated infarct size (median 17.7% versus 18.3%; p = NS). In the 33 patients in the streptokinase group, there was a highly significant decrease from predicted to final myocardial infarct size (median 21.9% versus 16.2%; p less than 0.0002). This decrease was found for both anterior (median 23.7% versus 19.5%; p less than 0.03) and inferior (median 21.9% versus 12.0%; p = 0.001) infarct locations. Multiple regression analysis adjusting for differences in predicted infarct size confirmed the significance of streptokinase on the difference in infarct size (p = 0.006). Based on the variability of the percent change from predicted to final infarct size in the control group, a threshold decrease greater than or equal to 20% is required for identification of salvage.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine B, Rigshospitalet, University of Copenhagen, School of Medicine, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Clemmensen
authors.forename: P
authors.initials: P
authors.lastname: Grande
authors.forename: K
authors.initials: K
authors.lastname: Saunamäki
authors.forename: F
authors.initials: F
authors.lastname: Pedersen
authors.forename: J H
authors.initials: JH
authors.lastname: Svendsen
authors.forename: N B
authors.initials: NB
authors.lastname: Wagner
authors.forename: J
authors.initials: J
authors.lastname: Granborg
authors.forename: J K
authors.initials: JK
authors.lastname: Madsen
authors.forename: C
authors.initials: C
authors.lastname: Haedersdal
authors.forename: G S
authors.initials: GS
authors.lastname: Wagner
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D012044:Regression Analysis; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy
chemical_list: D013300:Streptokinase; D001241:Aspirin